denosumab
114161
Phase 3 small_molecule completed
Quick answer
denosumab for Osteoporosis, Postmenopausal is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Osteoporosis, Postmenopausal
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed